Conformis to Present at the 32nd Annual J.P. Morgan Healthcare Conference
Bedford, Mass. – January 7, 2014 – Conformis, Inc., a medical device company pioneering patient-specific orthopedic implants, will present at the 32nd Annual J.P. Morgan Healthcare Conference in San Francisco, California. Dr. Philipp Lang, Chairman and CEO of Conformis, will discuss the company’s proprietary technology for patient-specific implants and instruments, its unique Just-In-Time (JIT) delivery model and novel, innovative, 3-D additive manufacturing technologies. Dr. Lang’s presentation will begin at 4 PM (PT) on Wednesday, January 15, 2014.
About Conformis, Inc.
Conformis, Inc. is a privately-held medical device company that is pioneering a patient-specific approach to orthopedic implants and instrumentation. Its proprietary technology is supported by more than 375 patents and patent applications. Conformis’ award winning partial and total knee replacement solutions, the iUni® G2, iDuo® G2 and iTotal® G2, are individually designed for each patient. Potential advantages compared to traditional off-the-shelf implants include faster recovery, shorter hospital stay, less blood loss, more bone preservation, and better functional outcomes. Conformis products are provided in a pre-sterilized single package delivery system that can help hospitals reduce costs associated with instrument re-sterilization and result in faster set-up, procedure and turnover time. The iUni® G2, iDuo® G2 and iTotal® G2, have been cleared by the U.S. FDA and are CE Marked in Europe.
Conformis is the leader in additive manufacturing in the orthopedic and medical device space. Conformis is the only orthopedic company that offers Just-In-Time (JIT) manufacturing with a single-package delivery system, resulting in greatly enhanced use of working capital.
Conformis technology is broadly applicable to all joints. The company is expanding into new applications and indications.
New Clinical Study Finds Bilateral Knee Patients Prefer Conformis’ Fully Personalized Solution Over Competitive Off-the-Shelf Implants by a Factor of Over 10 to 1
Study included only patients with a fully personalized Conformis implant in one knee after previously receiving a competitive off-the-shelf implant
Conformis iTotal® CR Knee Replacement System Awarded “7A” Performance Rating from the U.K.’s Orthopaedic Data Evaluation Panel
Independently verified assessment of the performance of the fully personalized iTotal CR system over a 7-year period confirms that it meets the panel’s demanding standards